Login to Your Account

Other News To Note

Monday, August 15, 2011
• Kineta Inc., of Seattle, received a $2.8 million Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease to support work on a new class of antiviral drugs. Kineta's program focuses on agonists of the retinoic acid inducible gene 1 innate immune pathway and is designed to target RNA viruses such as hepatitis C, influenza, West Nile virus, respiratory syncytial virus, Dengue fever and the common cold.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription